Regulatory Inspection Details
The US Food and Drug Administration (USFDA) conducted an onsite inspection of the pharmacovigilance and post marketing surveillance system at Zydus Lifesciences Limited's office based in New Jersey, USA.
Inspection Timeline
The inspection was conducted over a four-day period from September 22, 2026, to September 25, 2026.
Inspection Outcome
The inspection concluded with NIL observations, indicating that the company's pharmacovigilance and post-marketing surveillance systems fully comply with USFDA regulatory requirements.
Regulatory Disclosure Context
This announcement is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, requiring disclosure of material events to stock exchanges and investors.
Significance
The successful inspection with zero observations represents a significant regulatory compliance achievement for the company's US operations, particularly in the critical area of drug safety monitoring and post-market surveillance systems.